GlassScriptPhysician profile
Katherine Holdwick
NPI 1912400136
$2,324.00
in general payments reported to CMS, 2019-2025
33 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $453 · 2022: $426 · 2023: $390 · 2024: $568 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,444.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $445.75 | 2021-2025 | |
| Novo Nordisk INC | $235.15 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $216.68 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $169.40 | 2021-2025 | Mounjaro, Emgality, Jardiance |
| Merck Sharp & Dohme LLC | $121.14 | 2022-2024 | Gardasil, Gardasil 9, Vaxelis |
| Glaxosmithkline, LLC. | $112.79 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $103.10 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $97.02 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.77 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.01 | 2022-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $65.44 | 2021 | |
| Genentech USA, INC. | $60.56 | 2021-2022 | |
| Amgen INC. | $53.75 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.58 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $41.58 | 2023-2025 | Sunosi, Auvelity |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $38.63 | 2022 | |
| Ironshore Pharmaceuticals INC. | $37.03 | 2023-2024 | Jornay Pm |
| Mylan Specialty L.P. | $33.12 | 2023 | Yupelri |
| Janssen Pharmaceuticals, INC | $28.31 | 2021 | |
| Corium, LLC | $27.60 | 2022 | |
| Vanda Pharmaceuticals INC. | $26.86 | 2025 | Fanapt |
| Shield Therapeutics INC | $24.26 | 2024 | |
| Pfizer INC. | $21.04 | 2025 | |
| Biogen, INC. | $20.38 | 2024 | Spinraza |
| Astellas Pharma US INC | $19.73 | 2025 | Veozah |
| Ascensia Diabetes Care US INC. | $17.73 | 2025 | |
| Tolmar, INC. | $16.64 | 2024 | |
| Lundbeck LLC | $15.88 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $15.26 | 2021 | |
| Pulmonx Corporation | $15.14 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Cranial Technologies, INC | $14.63 | 2024 | Doc Band |
| Exact Sciences Corporation | $14.62 | 2025 | The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $13.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Holdwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.